Étiquette : cannabinoïdes

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses, Will Lawn et al., 2016

Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis ‘amotivational’ hypotheses Will Lawn, Tom P. Freeman, Rebecca A. Pope, Alyssa Joye, Lisa Harvey, Chandni Hindocha, Claire Mokrysz, Abigail Moss, Matthew B. Wall, Michael A.P. Bloomfield, Ravi K. Das, Celia J.A. Morgan, David J. Nutt, H. Valerie Curran Psychopharmacology, 2016, 233, 3537–3552 Doi : 10.1007/s00213-016-4383-x   Abstract Rationale : Anecdotally, both acute and chronic cannabis use have been associated with apathy, amotivation, and other reward processing deficits. To date, empirical support for these effects is limited, and no previous studies have assessed both acute effects of Δ-9-tetrahydrocannabinol (THC) and [...]

Lire la suite

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients, Jeffrey Y. Hergenrather et al., 2020

Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients Jeffrey Y. Hergenrather, Joshua Aviram, Yelena Vysotski, Salvatore Campisi-Pinto, Gil M. Lewitus and David Meiri. Rambam Maimonides Medical Journal, 2020, 11, (1), e0001 Doi : 10.5041/RMMJ.10384   Methods : Participants were adult patients licensed for medical cannabis (MC) treatment who also reported a diagnosis of ADHD by a physician. Data on demographics, ADHD, sleep, and anxiety were collected using self-report questionnaires. Data collected on MC treatment included administration route, cultivator, cultivar name, and monthly dose. Comparison statistics were used to evaluate differences in reported parameters between low (20–30 g, n=18) and [...]

Lire la suite

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, 2019

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367   Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]

Lire la suite

Harmful Effects of Smoking Cannabis : A Cerebrovascular and Neurological Perspective, Sabrina Rahman Archie et al., 2019

Harmful Effects of Smoking Cannabis : A Cerebrovascular and Neurological Perspective Sabrina Rahman Archie and Luca Cucullo Frontiers in Pharmacology, 2019, 10, Article 1481. doi : 10.3389/fphar.2019.01481   Apart from being used as a medicine, cannabis or marijuana is the most widely abused recreational drug all over the world. The legalization and decriminalization of cannabis in Canada and various states of USA may be the underlying reason of the widespread popularity of it among young population. Various studies have reported about the relationship between cannabis use and different detrimental effects like cardiovascular, cerebrovascular, and neurological complications among different age groups. Specifically, the young population is [...]

Lire la suite

The Psychiatric Consequences of Cannabinoids, Joao P. De Aquino et al., 2018

The Psychiatric Consequences of Cannabinoids Joao P. De Aquino, Mohamed Sherif, Rajiv Radhakrishnan, John D. Cahill, Mohini Ranganathan and Deepak C. D’Souza Clinical Therapeutics, 2018, 40, (9), 14481456 Doi : 10.1016/j.clinthera.2018.03.013   ABSTRACT With rising rates of cannabis use in the general population and an increasing number of US states legalizing both recreational and medical cannabis use, it is important to be informed about the adverse consequences of cannabinoids. This Commentary provides an overview of the psychiatric effects of plant-based and synthetic cannabinoids, differentiating acute effects from effects associated with persistent use. Cannabinoids produce multiphasic and dose dependent effects on anxiety, mood, and perception, in addition [...]

Lire la suite

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species, Faith Borgan et al., 2019

The effects of cannabinoid 1 receptor compounds on memory : a meta-analysis and systematic review across species Faith Borgan, Katherine Beck, Emma Butler, Robert McCutcheon, Mattia Veronese, Anthony Vernon, Oliver D. Howes Psychopharmacology, 2019 Doi : 10.1007/s00213-019-05283-3   Abstract Rationale : While cannabis-based medicinal products have been shown to be effective for numerous neurological and psychiatric disorders, the evidence base regarding their adverse cognitive effects is poorly understood. The cannabinoid 1 receptor modulates memory performance via intracellular and extracellular mechanisms that alter synaptic transmission and plasticity. While previous literature has consistently shown that chronic cannabis users exhibitmarked cognitive impairments,mixed findings have been reported in the context [...]

Lire la suite

Cannabinoids in Pain Management and Palliative Medicine, Winfried Häuser et al., 2017

Cannabinoids in Pain Management and Palliative Medicine An Overview of Systematic Reviews and Prospective Observational Studies Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke The Deutsches Ärzteblatt International,  2017, 114, 627–634. Doi : 10.3238/arztebl.2017.0627   SUMMARY Background : There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. Methods : We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane [...]

Lire la suite

European Commission proposes unified EU vote on WHO cannabis scheduling recommendations, Alfredo Pascual, Marijuana Business Daily, 15 janvier 2020

European Commission proposes unified EU vote on WHO cannabis scheduling recommendations Published January 15, 2020 | By Alfredo Pascual https://mjbizdaily.com/european-commission-proposes-unified-eu-vote-on-who-cannabis-scheduling-recommendations/?utm_medium=email&utm_source=newsletter&utm_campaign=INTL_20200115_NEWS_Weekly   In advance of the March session of the United Nations Commission on Narcotic Drugs (CND), the European Union’s executive branch has proposed that EU member nations vote in favor of three of the six World Health Organization (WHO) cannabis scheduling recommendations. The European Commission “Proposal for a Council Decision” is meaningful because – if adopted by the Council of Europe – the EU countries would vote as a block at the CND session in Vienna and the three motions [...]

Lire la suite

Cannabis, Cannabinoids, and Sleep : a Review of the Literature, Kimberly A. Babson et al., 2017

Cannabis, Cannabinoids, and Sleep : a Review of the Literature Kimberly A. Babson, James Sottile, Danielle Morabito Current Psychiatry Reports, 2017, 19, 23 Doi : 10.1007/s11920-017-0775-9   Abstract Purpose of Review : The current review aims to summarize the state of research on cannabis and sleep up to 2014 and to review in detail the literature on cannabis and specific sleep disorders from 2014 to the time of publication. Recent Findings : Preliminary research into cannabis and insomnia suggests that cannabidiol (CBD) may have therapeutic potential for the treatment of insomnia. Delta-9 tetrahydrocannabinol (THC) may decrease sleep latency but could impair sleep quality long-term. Novel studies investigating [...]

Lire la suite

Le cannabigerol est efficace contre les infections par des bactéries résistantes aux antibiotiques, The Guardian du 19 Janvier 2020

Le cannabigerol est efficace contre les infections par des bactéries résistantes aux antibiotiques Le cannabigérol (CBG), un cannabinoïde de la plante de cannabis, s’avère pouvoir détruire les bactéries résistantes aux médicaments, suscitant l’espoir d’une nouvelle arme dans la lutte contre les superbactéries. Les scientifiques ont examiné cinq cannabinoïdes pour leurs propriétés antibiotiques et ont découvert que le cannabigérol (CBG) était particulièrement puissant pour tuer le Staphylococcus aureus résistant à la méthicilline (SARM), l’une des super-bactéries les plus courantes dans les hôpitaux. Après avoir vu l’efficacité de la substance contre les bactéries en laboratoire, les chercheurs ont décidé de tester la capacité du [...]

Lire la suite